IQVIA Holdings (IQVIA Holdings) ROCE %

: 11.20% (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. IQVIA Holdings's annualized ROCE % for the quarter that ended in Dec. 2023 was 11.20%.

IQVIA Holdings ROCE % Historical Data

The historical data trend for IQVIA Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IQVIA Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

4.17

4.01

7.62

9.07

10.67

IQVIA Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %																8.32	10.36	11.28	10.91	11.20

IQVIA Holdings ROCE % Calculation

IQVIA Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	2131	/	( ( (25337 - 5578)	+	(26681 - 6491) )	/ 2 )
	=	2131	/	( (19759	+	20190)	/ 2 )
	=	2131	/	19974.5
	=	10.67 %

IQVIA Holdings's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	2216	/	( ( (25977 - 6589)	+	(26681 - 6491) )	/ 2 )
	=	2216	/	( ( 19388	+	20190 )	/ 2 )
	=	2216	/	19789
	=	11.20 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

IQVIA Holdings (NYSE:IQV) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

IQVIA Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of IQVIA Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

IQVIA Holdings (IQVIA Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » IQVIA Holdings Inc (NYSE:IQV) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

IQV:Mexico QTS:Germany QTS:Germany I1QV34:Brazil

Address

2400 Ellis Road, Durham, NC, USA, 27703

Website

https://www.iqvia.com

IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The Research & Development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.

Executives

Kevin C Knightly	officer: Pres Info & Tech Solutions	1499 POST ROAD, FAIRFIELD CT 06824
Panagos Constantinos	officer: See Remarks	4280 EMPEROR BLVD, DURHAM NC 27703
Eric Sherbet	officer: See Remarks	100 IMS DRIVE, PARSIPPANY NJ 07054-4235
Keriann Cherofsky	officer: See Remarks	4280 EMPEROR BLVD, DURHAM NC 27703
Sheila A Stamps	director	C/O CIT GROUP, 1 CIT DRIVE, ATTN: GENERAL COUNSEL, LIVINGSTON NJ 07039
Morris Leslie Wims	director	4280 EMPEROR BLVD, DURHAM NC 27703
John Connaughton	director, 10 percent owner	BAIN CAPITAL PARTNERS LLC, JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116
Ronald E Bruehlman	officer: See Remarks	C/O IQVIA HOLDINGS, INC., 83 WOOSTER HEIGHTS ROAD, DANBURY CT 06810
Ronald A Rittenmeyer	director	5400 LEGACY DRIVE, PLANO TX 75024
Ari Bousbib	director, officer: Chairman, CEO & Pres	UNITED TECHNOLOGIES CORP, ONE FINANCIAL PLAZA, HARTFORD CT 06101
W Richard Staub	officer: See Remarks
Tpg Group Holdings (sbs) Advisors, Inc.	10 percent owner	C/O TPG GLOBAL, LLC, 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
Michael J Evanisko	director	BRAUN CONSULTING, 20 W KINZIE STREET SUITE 1600, CHICAGO IL 60610
Michael R Mcdonnell	officer: Chief Financial Officer	C/O IQVIA HOLDINGS INC., 83 WOOSTER HEIGHTS ROAD, DANBURY CT 06810
John M. Leonard	director	C/O INTELLIA THERAPEUTICS INC, 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139